According to the infectious disease expert the afro American women should be first vaccinated against human papillomavirus (HPV). This vaccine was recently approved by the FDA . This was publicly announced in the Lancet Infectious Disease by researchers at The Miriam Hospital and Brown Medical School.
They said that the best ay for distributing the vaccine is through school-based vaccination clinics. The commentary is in response to an article in the January edition of the journal posing the question, ‘Who should be vaccinated against human papillomavirus?’ as well a review piece on HPV infection in men in the same issue. The HPV vaccine protects women from acquiring two types of HPV, a sexually transmitted disease believed responsible for 70 percent of cervical cancer cases. Research shows that African American women are at twice the risk of dying from cervical cancer than Caucasian women.‘Although the reason for the disparity of HPV in African American women is not well understood – simply knowing that this group is disproportionately affected should lead to targeted vaccination efforts that administer the safe, effective, three-dose prevention tool to them,’ says Loida E. Bonney, MD, MPH, a research fellow at The Miriam Hospital and lead author. The authors suggest that developing a school-based vaccine delivery program would provide an effective strategy for reaching the broadest number of at-risk African American females.
‘School-based vaccine delivery surpasses traditional primary care provider vaccination rates, but this avenue is not widely used,’ Bonney says. At-risk adolescents, the group that would be targeted for the HPV vaccine, remain the most difficult to vaccinate because of various barriers to care including the need for parental consent to receive vaccines. Bonney and her colleagues feel that parental consent should be waived for the HPV vaccine as it is for other sexually transmitted infection-related health care, such as treatment for gonorrhea and chlamydia. In addition to school-based vaccination clinics, juvenile detention centers and prisons with high populations of African American adolescents and young adults are institutions the authors say should be actively targeted for vaccine delivery. Historically, multi-dose vaccines, such as the HPV vaccine, have been difficult to distribute successfully. Bonney cites the approval of the hepatitis B vaccine as an example.
Despite being made readily available in 1982, hepatitis B had low vaccination rates until a strategy was adopted for universal infant vaccinations in the early 1990's. The authors call for mandates and funding from the national level to support the development of early and aggressive intervention programs to avoid similar issues with distribution of the HPV vaccine. The article states that although HPV does not affect all groups equally, it is imperative that the most vulnerable populations be proactively reached from the start to avoid another generation of cervical cancer tragedies.
(Source: Eurekalert)
